Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dyslipidemia

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 22 articles: HTML format

Single Articles

June 2025
1. KOREN MJ, Vega RB, Agrawal N, Xu Y, et al
   An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.
   J Am Coll Cardiol. 2025;85:1996-2007.
   PubMed     Abstract available
   
   
   May 2025
2. NORDESTGAARD AT, Tybjaerg-Hansen A, Mansbach H, Kersten S, et al
   Target Populations for Novel Triglyceride-Lowering Therapies.
   J Am Coll Cardiol. 2025;85:1876-1897.
   PubMed     Abstract available
   
   
   
3. XIE X, Shi X, Zhang Y, Su S, et al
   Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.
   J Am Coll Cardiol. 2025;85:1821-1835.
   PubMed     Abstract available
   
   
   
4. RAY KK, Linnebjerg H, Michael LF, Shen X, et al
   Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.
   J Am Coll Cardiol. 2025;85:1803-1818.
   PubMed     Abstract available
   
   
   
5. BALLANTYNE CM, Gaudet D, Rosenson RS, Hegele RA, et al
   Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.
   J Am Coll Cardiol. 2025;85:1839-1854.
   PubMed     Abstract available
   
   
   November 2024
6. SUN Y, Lv Q, Guo Y, Wang Z, et al
   Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.
   J Am Coll Cardiol. 2024;84:2037-2047.
   PubMed     Abstract available
   
   
   
7. XU M, Wang Z, Zhang Y, Liu Y, et al
   Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.
   J Am Coll Cardiol. 2024;84:2026-2036.
   PubMed     Abstract available
   
   
   September 2024
8. TOTH PP
   Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter.
   J Am Coll Cardiol. 2024;84:1007-1009.
   PubMed    
   
   
   April 2024
9. WRIGHT RS, Leiter LA, Lesogor A, Ray KK, et al
   Reply: Evaluation of the Inclisiran Safety in High-Risk Populations.
   J Am Coll Cardiol. 2024;83:e129.
   PubMed    
   
   
   
10. JIANG X, Zhang Z, Ding H
    Evaluation of the Inclisiran Safety in High-Risk Populations.
    J Am Coll Cardiol. 2024;83:e127.
    PubMed    
    
    
    March 2024
11. SZAREK M, Bhatt DL, Miller M, Brinton EA, et al
    Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    J Am Coll Cardiol. 2024 Mar 15:S0735-1097(24)00384.
    PubMed     Abstract available
    
    
    
12. BLAHA MJ, Bhatia HS
    Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy.
    J Am Coll Cardiol. 2024 Mar 9:S0735-1097(24)00944.
    PubMed    
    
    
    December 2023
13. BALLANTYNE CM, Minhas AMK, Orringer CE
    Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
    J Am Coll Cardiol. 2023;82:2262-2264.
    PubMed    
    
    
    
14. WRIGHT RS, Koenig W, Landmesser U, Leiter LA, et al
    Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
    J Am Coll Cardiol. 2023;82:2251-2261.
    PubMed     Abstract available
    
    
    October 2023
15. GIDDING SS
    Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:1558-1563.
    PubMed     Abstract available
    
    
    August 2023
16. BEN-YEHUDA O
    Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal: A Clear Winner?
    J Am Coll Cardiol. 2023;82:411-413.
    PubMed    
    
    
    
17. LEE SJ, Joo JH, Park S, Kim C, et al
    Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    J Am Coll Cardiol. 2023;82:401-410.
    PubMed     Abstract available
    
    
    July 2023
18. KALRA DK, Vorla M, Michos ED, Agarwala A, et al
    Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:171-181.
    PubMed     Abstract available
    
    
    
19. MORALES J, Handelsman Y
    Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:161-170.
    PubMed     Abstract available
    
    
    May 2023
20. KAZI DS, DeJong C, Chen R, Wadhera RK, et al
    The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
    J Am Coll Cardiol. 2023;81:2103-2111.
    PubMed     Abstract available
    
    
    April 2023
21. CHOI D, Malick WA, Koenig W, Rader DJ, et al
    Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3.
    J Am Coll Cardiol. 2023;81:1621-1632.
    PubMed     Abstract available
    
    
    
22. BALLANTYNE CM, Banka P, Mendez G, Garcia R, et al
    Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
    J Am Coll Cardiol. 2023;81:1553-1564.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.